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Abstract 
Background: A 2010/11 audit of the RCEM-NPIS UK guidelines on antidote 
availability demonstrated variable stocking of antidotes for the management of 
poisoned patients; the guidelines were updated and republished in 2013.  
 
Aim: To assess if antidote stocking has improved since the 2010/11 audit and 
introduction of the 2013 guidelines. 
 
Methods: Questionnaires were sent to Chief Pharmacists at all 215 acute hospitals in 
England, Wales and Northern Ireland in October 2014. Data were collected on timing 
of availability (Category A antidotes should be available immediately, Category B 
within 1hour, Category C can be held supraregionally) and stock levels.  
 
Results: 169 (78.6%) responses were received. Atropine, calcium gluconate and 
flumazenil (Category A) were the only antidotes available in all hospitals within the 
recommended time and stock levels. Forty-one (24.3%) hospitals held every 
category A antidote; this increased to 81 (47.9%) for those holding at least one 
cyanide antidote and all other category A antidotes. The proportion of hospitals 
stocking Category A/B antidotes within the recommended time increased for 20 
(90.9%) category A/B antidotes. Fomepizole (Category B) availability increased to 
62.1% of hospitals from 11.4% in 2010/11. Other than penicillamine (63.3% 
hospitals), there was poor availability (2.4-36.1%) of Category C antidotes. 
 
Conclusion: Availability of category A and B antidotes has improved since the 
2010/11 audit and 2013 guidelines. However there remains significant variability 
particularly for Category C antidotes. More work is required to ensure that those 
treating poisoned patients have timely access to antidotes focusing particularly on 
Category C antidotes.  
 
 
 
Background 
Antidotes are an important component of the management of poisoned patients, and 
early and timely administration is important for the efficacy of many antidotes and 
optimum management of poisoned patients presenting to the Emergency 
Department. The Royal College of Emergency Medicine (RCEM) and National 
Poisons Information Service (NPIS) first issued national guidelines on the stocking of 
antidotes in 2006; these were updated in 2008 and again in 2013. [1] These 
guidelines provide clear recommendations for the timing of availability and minimum 
stock levels for antidotes in UK hospitals treating poisoned patients.  
 
A UK 2010/11 audit in England, Wales and Scotland demonstrated variable levels of 
antidote availability in hospitals across the country with significant improvement 
being required for compliance with the national guidelines. [2] In this audit, 30 
(15.3%) hospitals did not stock any antidote for toxic alcohol poisoning and 9 (4.6%) 
hospitals stocked no cyanide antidotes. [2] Studies in the USA, Canada and New 
Zealand have also shown significant problems in the availability of antidotes despite 
national guidance. [3,4,5,6]  
 
The RCEM/NPIS antidote guidelines were developed to provide advice to hospitals 
to ensure appropriate and timely availability of antidotes for the optimum 
management of poisoned patients. The antidotes are split into 3 different categories 
based on the urgency with which they may be required and also how frequently they 
are used. Category A antidotes are recommended to be available immediately within 
the Emergency Department. Category B antidotes should be available for use within 
1 hour (therefore, recommended to be stocked in the hospital). Category C antidotes 
are recommended to be held supra-regionally, because they are used less 
commonly and immediate treatment is generally not required. Having fewer sites 
holding these antidotes reduces the risk of wasting unused stock. The guidelines 
also recommend minimum stock levels based on the amount required for the 
treatment of an adult poisoned patient for the first 24 hours. [1] Antivenoms for non-
indigenous venomous animals are held supra-regionally and are subject to separate 
procurement and distribution arrangements through Public Health England.  
 
Changes introduced in the 2013 guidelines included alterations in categories for 
viper venom antiserum (from Category B to A) and pralidoxime (from Category B to 
Category C); the recommendation of a designated storage facility for antidotes within 
the ED; recommending fomepizole as the antidote of choice for toxic alcohol 
poisoning; and updating minimum stock levels to allow for the provision of the first 24 
hours of treatment. The 2013 RCEM/NPIS guideline was also supported by a letter 
from the Chief Pharmaceutical Officers for England, Wales and Scotland and the 
National Clinical Director for Emergency Care for NHS England. [1] 
 
This study aimed to assess if antidote stocking has improved since the 2010/11 audit 
and the introduction of the 2013 RCEM/NPIS Guidelines. 
 
Methods 
Questionnaires were sent to the Chief Pharmacists of all 215 acute hospitals in 
England (187 hospitals), Wales (16 hospitals) and Northern Ireland (12 hospitals). A 
separate audit is currently being undertaken in Scotland. Acute hospitals were 
defined as those with type 1 emergency departments (those open 24 hours and 
consultant led, with full resuscitation facilities) and/or acute medical admissions 
units.  
 
A questionnaire similar to that used in the 2010 audit [2] was created which included 
all of the antidotes on the RCEM/NPIS guidelines with tick boxes for the timing of 
availability and stock levels. Unlike the 2010 audit we included all of the antidotes 
included in the RCEM/NPIS guideline. In addition, as in the previous audit, 
intravenous lipid emulsion (ILE or ‘lipid rescue’) was also included although this is 
not currently listed in the guidelines.    
 
The questionnaire was sent electronically to Chief Pharmacists at the 215 identified 
hospitals in October 2014, requesting a response electronically or by post. A follow-
up electronic reminder was sent in December 2014; non-responders then received a 
telephone call to either the pharmacy department or medicines information service in 
January 2015. Responses received by 22nd March 2015 were included in the 
analysis.  
 
Questionnaire responses were collated in an Excel® spreadsheet and separated by 
country for analysis. For each antidote, the following data were collected: the number 
of hospitals stocking the antidote; availability within the recommended time 
(Category A should be immediately available within the Emergency Department; 
Category B should be available within 1 hour and Category C are recommended for 
supra-regional stocking); whether recommended stock levels were held; and time to 
availability if not stocked in the hospital.  
 
Results 
A total of 169 responses were received, equating to an overall response rate of 
78.6% (England: 145 responses (77.5% response rate), Wales: 13 (81.3%), and 
Northern Ireland: 11 (91.7%)). This was lower than the 2010-11 audit response rate 
of 87.5%. 
 
The availability, timing of availability and stock levels compared to the guidelines is 
shown in Tables 1-3 for Category A, B and C antidotes respectively. Figures 1 and 2 
compare the data to the 2010 audit [2] for availability of antidotes both within the 
recommended time and at minimum recommended stock levels. 
 
Category A: recommended for immediate availability in the ED 
41 (24.3%) hospitals held every Category A antidote for immediate availability and 
this increased to 81 (47.9%) for those holding at least one cyanide antidote and all 
other category A antidotes. Excluding cyanide antidotes and accounting for the 
recommendation for stocking either glyceryl trinitrate or isosorbide dinitrate, 9 out of 
15 (60%) Category A antidotes were available immediately at recommended stock 
levels in over 90% of hospitals. 
 
Atropine, calcium gluconate and flumazenil were the only Category A antidotes 
available in all hospitals with both the recommended availability and minimum stock 
levels. A number of other Category A antidotes (acetylcysteine, activated charcoal, 
calcium chloride, glucagon, naloxone and procyclidine) were available in all hospitals 
but not available immediately as recommended in the guidelines.  
 
Four cyanide antidotes are included in the guidelines in Category A. All hospitals 
stocked at least one antidote for cyanide poisoning; an improvement compared to 
the previous audit that found 4.6% of hospitals did not stock any cyanide antidote. 
There was an increase in the proportion of hospitals stocking hydroxocobalamin 
(21.4% in 2010 audit to 55.6% in 2015 audit), dicobalt edetate (73.5% to 82.2%) and 
sodium thiosulphate (66.3% to 77.5%), and a small decrease in the proportion of 
hospitals stocking sodium nitrite (57.1% to 56.2%).  
 
The guidelines recommend stocking either glyceryl trinitrate or isosorbide dinitrate 
for the treatment of toxin-related hypertension and all hospitals stocked at least one 
of these two treatments.  
 
Category B: recommended to be available within 1 hour 
As shown in Table 2, all Category B antidotes were available within 1 hour in 30 
(17.6%) hospitals and 62 (36.7%) had all Category B antidotes excluding 
phentolamine and/or pyridoxine (for which there are known current 
supply/manufacturing problems) available within 1 hour. Octreotide and protamine 
were the only category B antidotes available within one hour and at recommended 
stock levels in over 90% of hospitals. 
 
Fomepizole is the antidote of choice for toxic alcohol (ethylene glycol, diethylene 
glycol and methanol) poisoning and was available within 1 hour in 124 (73.4%) 
hospitals, an increase from 16.8% of hospitals in the 2010 audit. 89 (52.7%) 
hospitals had both fomepizole and IV ethanol available within the recommended 1 
hour, 36 (21.3%) had only fomepizole and 33 (19.5%) had only IV ethanol available; 
there were only 11 (6.5%) hospitals where neither antidote was available within 1 
hour, compared to 17.3% of hospitals in the 2010-11 audit.    
 
Category C: can be held supra-regionally 
As shown in Table 3, the Category C antidotes were available, as expected, in fewer 
hospitals. There was significant variation from stocking of glucarpidase in only 4 
(2.4%) hospitals to stocking of penicillamine in107 (63.3%) hospitals. Information 
about the source of availability for hospitals not stocking category C antidotes is also 
shown in table 3.  
 
Intravenous lipid emulsion was stocked in 166 (98.2%) hospitals and was 
immediately available in 121 (71.6%) hospitals. In the 2010-2011 audit it was 
stocked in 87.2% of hospitals and immediately available in 62.2%. 
 
For comparison between individual countries, there was availability of the 
recommended antidotes within the recommended time in at least 90% of hospitals 
for 10/20 (50%) Category A  and 8/14 (57.1%) Category B antidotes in England, 
12/20 (60%) A and 7/14 (50%) in Wales and 13/20 (65%) A and 9/14 (64.3%) B in 
Northern Ireland. 
 
Discussion 
The availability of most antidotes, particularly those in Category A and Category B, 
has improved since the 2010/11 audit and the introduction of the latest guidelines in 
2013. There have been large increases in timely availability of hydroxocobalamin, 
viper venom antiserum, cyproheptadine and fomepizole. The percentage of hospitals 
stocking antidotes available within the recommended time increased for 20 out of 22 
(90.9%) category A and B antidotes included in both audits. However, despite the 
introduction and update of the national guidelines with the support of the Chief 
Pharmaceutical Officer for England and the National Clinical Director for Emergency 
Care for England, less than a quarter of hospitals have every Category A antidote 
available for immediate use. A lack of availability of antidotes for use in emergency 
situations has significant clinical implications for the optimum management of 
poisoned patients. During this audit period there was a known supply problem due to 
the discontinuation of production of phentolamine in the UK. This was out of control 
of the hospitals stocking antidotes. Supply problems with sodium nitrite and 
acetylcysteine were also reported, although the results suggest acetylcysteine 
availability was not affected. Other antidotes were unaffected by supply problems.  
 
Availability of cyanide poisoning antidotes has improved and all hospitals responding 
stocked at least one of the recommended antidotes. Dicobalt edetate is 
recommended for severe cases in which there is a strong clinical certainty of cyanide 
poisoning and is now available immediately in 82.2% of hospitals. Hydroxocobalamin 
is recommended for severe cyanide poisoning related to smoke inhalation (with 
severe lactic acidosis, coma or cardiovascular compromise); availability has more 
than doubled since the previous audit but less than half of hospitals had the 
recommended stock available for immediate treatment. Cyanide poisoning antidotes 
are used in the management of critically unwell patients and delays in antidote 
administration could result in mortality.  
 
Despite improvements in availability of category A antidotes, the lack of immediate 
availability in some hospitals for antidotes including calcium gluconate gel, dicobalt 
edetate, 8.4% sodium bicarbonate and viper venom antiserum is of concern 
particularly in view of the urgency with which their use may be required. In view of 
clear guidelines and recommendations, it would be difficult to defend a clinical 
incident occurring due to inadequate access to these antidotes.  
 
Fomepizole was designated the antidote of choice for ethylene glycol or methanol 
poisoning in the 2013 guidelines and recommended as a Category B antidote to be 
stocked for availability within one hour. There has been a significant increase in the 
availability of fomepizole within one hour from 16.8% to 73.4% of hospitals. 
Therefore many hospitals now have timely access to the preferred treatment for toxic 
alcohol poisoning, although there remain a small number (6.5%) with no appropriate 
antidote stocked for treating this important and potentially serious life-threatening 
poisoning.  
 
Inadequate stocking of antidotes has been a concern across the world despite there 
being numerous international guidelines. Studies in Canada, the US and New 
Zealand have all demonstrated inadequate stocking of antidotes and the cost and 
infrequent use of antidotes have been suggested as contributing factors.  [3,4,5,6] 
Canadian studies before and after the introduction of guidelines for antidote stocking 
have demonstrated improvements in availability of antidotes but a persistent lack of 
stock for many essential antidotes in some hospitals. [3,4] Use of a national Internet 
accessible antidote database has been suggested as a method to share information 
and improve availability. [6] Transferring antidotes from other hospitals can result in 
delays in administration of antidotes, partly due to the infrequent and unplanned 
nature of the arrangements. [5]  
 
A recent US study has illustrated the impact of drug shortages on the supply of 
antidotes for the management of poisoned patients. [7] In this study, 141 (8.1%) of 
US drug shortages over a 13 year period were for drugs used to treat poisoned 
patients, with a median shortage duration of 164 days. There have been problems 
with the supply of a number of antidotes in the UK in recent years. This was 
illustrated in our audit by the poor stocking of phentolamine which was only available 
in about half of the hospitals; UK production of phentolamine was discontinued in 
August 2012 and since this time guidance on alternative antidotes have been 
available from NPIS on TOXBASE. [8] Pyridoxine was also relatively poorly stocked; 
currently the high strength pyridoxine product is not routinely available and hospitals 
need a minimum stock requirement of 100 vials for the treatment of isoniazid 
poisoning.  
 
The high cost of some antidotes and the need to replace stock which may expire 
before being used are possible reasons for poor stocking. Examples include digoxin-
specific antibody fragments and fomepizole. A Canadian study found that the shelf 
life, replacement of stock and frequency of use are all important in determining cost 
to departments along with the cost of individual drugs. [9] The American College of 
Medical Toxicology and American Academy of Clinical Toxicology have suggested 
that the recent FDA Safety and Innovation Act could help the process of extending 
the shelf life for some rarely used antidotes as part of other methods to improve 
availability and reduce shortages. [10] However, cost and supply problems alone do 
not account for the lack of available antidote stocks; activated charcoal and 
methylthionium chloride are two examples of less expensive antidotes that are 
currently inadequately stocked. 
 
There was significant variation in the stocking of supraregional Category C antidotes. 
Data on the time to availability of Category C antidotes was poorly recorded and this 
limited the assessment of the effectiveness of supra-regional stocking systems. In 
many cases the nearest source for availability of category C antidotes was recorded 
as “unknown”, suggesting a lack of co-ordination or available location information for 
supra-regional antidotes.  
 
Few hospitals stock category C antidotes and for those that do not, generally less 
than half provided information on where they would source the antidote. It is 
important for hospitals not stocking category C antidotes to have plans in place to 
source these antidotes when required. For example, sodium calcium edetate is 
indicated for the treatment of lead encephalopathy, although this a rare diagnosis, 
prompt treatment is required. In this audit 16.8% of hospitals stocked the antidote 
and for those that did not only 44% were able to provide information on where it 
would be sourced from. Further work is urgently needed in this area to facilitate 
systematic supraregional availability of these less commonly used antidotes to 
ensure that they are available in a timely manner when required for the management 
of poisoned patients.  
 
Limitations 
Compared to the 2010-11 audit, Scotland was not included and Northern Ireland was 
included. The audit was delayed in Scotland until recommendations were made for 
the access of rarely used medicines and a separate audit using the same 
questionnaire is now being undertaken. The overall response rate was lower on this 
occasion (78.6% vs 87.5%). There is a risk that hospitals not responding have 
comparatively poor levels of stock and the lower response rate may have made 
some contribution to the apparent improvements demonstrated. However, there was 
an absolute increase in the number of hospitals stocking antidotes including 
fomepizole, cyproheptadine, vipervenom antiserum, dicobalt edetate and 
hydroxocobalamin compared to the previous audit despite the lower response rate. 
There were also changes to categories, such as viper venom antiserum being added 
to Category A and a larger number of antidotes were included in the audit this year. 
These factors affect the comparison between the two audits. There were also known 
manufacturing or supply problems with phentolamine, acetylcysteine and sodium 
nitrite during the audit period.  
 
Conclusion 
Availability of category A and B antidotes has improved in England, Wales and 
Northern Ireland since the 2010 audit and the updated 2013 RCEM/NPIS antidote 
stocking guidelines. However there is still significant variability in the availability of 
antidotes, particularly the Category C supra-regional antidotes, and a national 
mechanism is needed to improve and ensure systematic availability of these 
Category C antidotes.  
 
References 
1. CEM & NPIS. Guideline on antidote availability for emergency departments. 
(December 2013). Available from http://www.rcem.ac.uk/Shop-
Floor/Clinical%20Guidelines/College%20Guidelines/ (accessed 10th April 2015) 
2. Thanacoody RH, Aldridge G, Laing W, et al. National audit of antidote stocking in 
acute hospitals in the UK. EMJ 2013;30:393-396. 
3. Wiens MO, Zed PJ, Lepik KJ, et al. Adequacy of antidote stocking in British 
Columbia hospitals: the 2005 Antidote Stocking Study. Can J Emerg Med 
2006;8(6):409-16. 
4. Bailey B, Bussieres JF, Dumont M. Availability of antidotes in Quebec hospitals 
before and after dissemination of guidelines. Am J Health Syst Pharm 
2003;60(22):2345-9. 
5. Dart RC, Borron SW, Caravati EM, et al. Expert consensus guidelines for 
stocking of antidotes in hospitals that provide emergency care. Ann Emerg Med 
2009;54:386-94. 
6. Fountain JS, Sly B, Holt A, MacDonnell S. Availability of antidotes, antivenoms, 
and antitoxins in New Zealand hospital pharmacies. N Z Med J 
2015;128(1411):23-33. 
7. Mazer-Amirshahi M, Hawley KL, Zocchi M, et al. Drug shortages: Implications for 
medical toxicology. Clin Toxicol (Phila) 2015;53(6):519-24. 
8. National Poisons Information Service. Phentolamine (antidote). 
http://www.toxbase.org/General-Info/Antidotes---doses-and-
sources/Phentolamine-antidote/ (accessed 10th April 2015) 
9. Sivilotti ML, Eiseen JS, Lee JS, Peterson RG. Can emergency departments not 
afford to carry essential antidotes? Can J Emerg Med 2002;4(1):22-33.  
10. ACMT, AACT. Antidote shortages in the USA: Impact and response. Journal of 
Medical Toxicology 2015;11:144-146.  
 
 
 
Table 1 Availability of Category A antidotes that should be immediately available. N= 169. 
 
 
 
Antidote 
2014-2015 
Number (%) 
of hospitals 
stocking 
the antidote 
2014-2015  
Number (%) 
of hospitals 
with the 
antidote 
available 
immediately 
2010-2011  
%Hospitals 
with the 
antidote 
available 
immediately‡ 
%Change from 
2010 to 2015 audit 
in immediate 
availability (+/-%) 
[95% CI] 
Acetylcysteine 169 (100) 168 (99.4) 95.9 +3.5 [0.5 to 6.5] 
Activated charcoal 169 (100) 167 (98.8) 95.4 +3.4 [0.1 to 6.8] 
Atropine 169 (100) 169 (100) NA NA 
Calcium chloride 169 (100) 159 (94.1) NA NA 
Calcium gluconate 169 (100) 169 (100) NA NA 
Calcium gluconate gel 147 (87.0) 137 (81.1) 68.4 +12.7 [3.9 to 21.5] 
Dicobalt edetate 156 (92.3) 140 (82.2) 73.5 +9.3 [1.0 to 17.8] 
Flumazenil 169 (100) 169 (100) 90.3 +9.7 [5.6 to 13.8] 
Glucagon 169 (100) 161 (95.3) 89.3 +6.0 [0.6 to 11.4] 
Glyceryl Trinitrate* 155 (91.7) 150 (88.8) NA NA 
Hydroxocobalamin 107 (63.3) 94 (55.6) 21.4 +34.2 [24.8 to 43.6] 
Isosorbide dinitrate* 90 (53.3) 57 (33.7) NA NA 
Methylthionium chloride 163 (96.4) 145 (85.5) 74.5 +11.0 [3.3 to 19.4] 
Naloxone 169 (100) 168 (99.4) 92.9 +6.5 [2.8 to 10.3] 
Procylidine 169 (100) 165 (97.6) NA NA 
Sodium bicarbonate 8.4% 164 (97.0) 155 (91.7) NA NA 
Sodium bicarbonate 1.26 or 1.24% 161 (95.3) 139 (82.2) NA NA 
Sodium nitrite 104 (61.4) 95 (56.2) 57.1 -0.9 [-9.3 to 11.1] 
Sodium thiosulphate 149 (88.2) 131 (77.5) 66.3 +11.2 [2.1 to 20.3] 
Viper venom antiserum† 134 (84.8) 118 (74.7) 44.9 +29.8 [20.1 to 39.5] 
 
*Either glyceryl trinitrate or isosorbide dinitrate are recommended to be stocked.  
†Viper venom antiserum does not need to be stocked in Northern Ireland. (N= 158)  Category B in previous 
guidelines: to be available within 1 hour.  
‡Not all antidotes were included in the 2015 audit (these are marked in the table as NA) 
 Table 2 Availability of category B antidotes that should be available within 1 hour.  
 
 
 
Antidote 
2014-2015 
Number (%) of 
hospitals 
stocking the 
antidote 
2014-2015 
Number (%) of 
hospitals with 
the antidote 
available within 
1 hour 
2010-2011 
%Hospitals 
with the 
antidote 
available within 
1 hour‡ 
% Change from 
2010 audit in 
availability within 1 
hour (+/-%) [95%CI] 
Calcium folinate 156 (92.3) 148 (87.6) 77.0 +10.6 [2.8 to 18.2]  
Cyproheptadine 134 (79.3) 131 (77.5) 45.9 +31.6 [22.2 to 41.0] 
Dantrolene 165 (97.6) 161 (95.3) 93.4 +1.9 [-2.8 to 6.6] 
Deferoxamine 166 (98.2) 163 (96.4) 91.3 +5.1[0.3 to 10.0] 
Digoxin-Specific Antibody 
Fragments 
157 (92.9) 157 (92.9) 82.1 +10.8 [4.1 to 17.4] 
Ethanol IV 125 (74.0) 122 (72.2) 72.4 -0.2 [-8.9 to 9.5] 
Fomepizole 128 (75.7) 124 (73.4) 16.8 +56.6 [48.1 to 68.0] 
Mesna* 161 (95.3) 155 (91.7) NA NA 
Octreotide 168 (99.4) 163 (96.4) 84.2 +12.2 [6.5 to 18.1] 
Phentolamine† 87 (51.5) 84 (49.7) NA NA 
Phytomenadione 169 (100) 165 (97.6) 93.9 +3.7 [0.3 to 7.8] 
Polyethylene glycol 161 (95.3) 156 (92.3) 84.2 +8.1 [1.6 to 14.6] 
Protamine 169 (100) 169 (100.0) NA NA 
Pyridoxine 125 (74.0) 117 (69.2) NA NA 
 
*Mesna is only required in hospitals commonly using cyclophosphamide. 
 †Phentolamine has been discontinued. Unlicensed preparations are stocked in some hospitals. 
‡Not all antidotes were included in the 2010 audit (these are marked as NA in the table) 
 
 
 
 
Table 3 Availability of Category C antidotes recommended for supra-regional stocking and for 
hospitals not stocking the antidotes information provided on the source of availability. 
Antidote 
No. (%) of 
hospitals 
stocking 
antidote 
No. (%) of 
hospitals not 
stocking 
antidote 
For hospitals not stocking the antidote 
No. (%) providing 
information on 
source of 
availability 
No. (%) 
reporting 
unknown 
source of 
availability 
No. (%) 
providing no 
data on 
potential 
availability 
Berlin blue 
 
11 (6.5) 158 (93.5) 58 (36.7) 10 (6.3) 90 (57.0) 
Botulinum 
antitoxin 
 
25 (14.8) 144 (85.2) 76 (52.8) 5 (3.5) 63 (43.8) 
Dimercaprol 
 
60 (35.5) 109 (64.5) 48 (44.0) 3 (2.8) 58 (53.2) 
Glucarpidase 
 
4 (2.4) 165 (97.6) 26 (15.8) 23 (13.9) 116 (70.3) 
Penicillamine 
 
107 (63.3) 62 (36.7) 18 (29.0) 5 (8.1) 39 (62.9) 
Pralidoxime 
 
61 (36.1) 108 (63.9) 59 (54.6) 4 (3.7) 45 (41.7) 
Sodium calcium 
edetate 
28 (16.6) 141 (83.4) 62 (44.0) 10 (7.1) 60 (48.9) 
Succimer 
(DMSA) 
 
13 (7.7) 156 (92.3) 56 (35.9) 15 (9.6) 85 (54.5) 
Unithiol (DMPS) 
 
9 (5.3) 160 (94.7) 58 (36.3) 14 (8.8) 88 (55.0) 
Figure 1 Percentage of hospitals holding recommended stock levels of category A antidotes for 
immediate availability. Comparison to 2007 and 2010-11 audits.   
*Viper venom antiserum has been changed to category A (having previously been in category B) in the 2013 guidelines and is 
not required in Northern Ireland. 
 
 
 
Figure 2 Percentage of hospitals holding recommended stock levels of category B antidotes for 
availability within 1 hour. Comparison to 2007 and 2010-11 audits. 
 
 
 
Appendix 1: The questionnaire is attached as a separate file. 
